Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers

Xenobiotica

Volumn 41, Issue 4, 2011, Pages 297-311

  Stopfer, Peter ^a   Rathgen, Karin ^a   Bischoff, Daniel ^a   Lüdtke, Silke ^a   Marzin, Kristell ^a   Kaiser, Rolf ^a   Wagner, Klaus ^a   Ebner, Thomas ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

BIBF 1120; metabolism; pharmacokinetic profile

Indexed keywords

CARBON 14; FIBROBLAST GROWTH FACTOR RECEPTOR; INTEDANIB; N DEMETHYLASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR;

ADULT; ARTICLE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACOKINETICS; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; ANGIOGENESIS INHIBITORS; ENZYME INHIBITORS; FECES; HALF-LIFE; HUMANS; INDOLES; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 79952943038     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2010.545452     Document Type: Article

References (24)

1. Benet LZ, Spahn-Langguth H, Iwakawa S, Volland C, Mizuma T, Mayer S, Mutschler E, Lin ET. (1993). Predictability of the covalent binding of acidic drugs in man. Life Sci 53:PL141-PL146.
2. Camidge DR, Conkling P, Stephenson J, Glassman PM, Zhao Y, Kaiser R, Stopfer P. (2008). Pharmacokinetic (PK) analysis of a phase I study of continuous oral treatment with the angiokinase inhibitor BIBF 1120, in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 26:Abstract 3567.
3. Camidge DR, Conkling P, Stephenson J, Shapiro D. (2007). A phase I study of continuous oral treatment with the triple angiokinase inhibitor BIBF 1120 together with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2:S730.
4. Carmeliet P, Jain RK. (2000). Angiogenesis in cancer and other diseases. Nature 407:249-257.
5. du Bois A, Huober J, Stopfer P, Pfisterer J, Wimberger P, Loibl S, Reichardt VL, Harter P. (2010). A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. Ann Oncol 21:370-375.
6. Ebner T, Heinzel G, Prox A, Beschke K, Wachsmuth H. (1999). Disposition and chemical stability of telmisartan 1-Oacylglucuronide. Drug Metab Dispos 27:1143-1149. (Pubitemid 29463600)
7. Ellis PM, Kaiser R, Zhao Y, Stopfer P, Gyorffy S, Hanna N. (2010). Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clin Cancer Res 16:2881-2889.
8. Hanna N, Ellis P, Stopfer P, Shapiro D, Gyorffy S. (2007). A phase I study of continuous oral treatment with the triple angiokinase inhibitor BIBF 1120 together with pemetrexed in previously treated patients with non-small cell lung cancer. J Thorac Oncol 2:S717.
9. Herbst RS. (2006). Therapeutic options to target angiogenesis in human malignancies. Expert Opin Emerg Drugs 11:635-650. (Pubitemid 44735590)
10. Hignite CE, Tschanz C, Huffman DH, Azarnoff DL. (1978). Quantitation of N-demethylantipyrine in biological samples and isolation and characterization of its glucuronic acid conjugate. Drug Metab Dispos 6:288-295. (Pubitemid 8352943)
11. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ. (2008). BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68:4774-4782.
12. Hu Q, Noll RJ, Li H, Makarov A, Hardman M, Cooks RG. (2005). The Orbitrap: A new mass spectrometer. J Mass Spectrom 40:430-443. (Pubitemid 40637866)
13. Ledermann JA, Rustin GJ, Hackshaw A, Kaye SB, Jayson G, Gabra H, James LE, Bell S, Temple G, Gabra H, James LE, Bell S, Temple G. (2009). A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC). J Clin Oncol 2715s.
14. Lee CP, Attard G, Poupard L, Nathan PD, de Bono JS, Temple GM, Stefanic M, Padhani AR, Judson IR, Rustin GJ. (2005). A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in patients with advanced solid malignancies. J Clin Oncol 23:3054.
15. Meuldermans W, Lauwers W, Knaeps A, Heykants J. (1977). In vitro metabolism of lidoflazine by rat and dog liver fractions. Arzneimittelforschung 27:828-832. (Pubitemid 8076360)
16. Mross K, Stefanic M, Gmehling D, Frost A, Baas F, Unger C, Strecker R, Henning J, Gaschler-Markefski B, Stopfer P, de Rossi L, Kaiser R. (2009). Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 16:311-319.
17. Obach RS, Reed-Hagen AE, Krueger SS, Obach BJ, O'Connell TN, Zandi KS, Miller S, Coe JW. (2006). Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos 34:121-130. (Pubitemid 43042653)
18. Okamoto I, Kaneda H, Satoh T, Okamoto W, Miyazaki M, Morinaga R, Ueda S, Terashima M, Tsuya A, Sarashina A, Konishi K, Arao T, Nishio K, Kaiser R, Nakagawa K. (2010). Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol Cancer Ther 9:2825-2833.
19. Raymond E, Goldwasser F, Bousquet C, Le Tourneau S, Faivre S, de Mont-Serrat H, Rouyrre N, Stopfer P, Stefanic M, Kaiser R, Misset JL (2007). A phase I dose escalation and pharmacokinetic study of BIBF 1120, a novel tyrosine kinase inhibitor against VEGFR, PDGFR and FGFR, in combination with docetaxel in advanced chemonaïve hormone refractory prostate cancer patients (HRPC). Eur J Cancer 5:S108.
20. Reck M, Kaiser R, Eschbach C, Stefanic M, Love J, Gatzemeier U, von Pawel J. (2007). Phase II double blind study to investigate efficacy and safety of the triple angiokinase inhibitor BIBF 1120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2:S333.
21. Schütz H, Feldmann KF, Faigle JW, Kriemler HP, Winkler T. (1986). The metabolism of 14C-oxcarbazepine in man. Xenobiotica 16:769-778.
22. Sidelmann UG, Hansen SH, Gavaghan C, Carless HAJ, Lindon JC, Farrant RD, Wilson ID, Nicholson JK. (1996). Measurement of internal acyl migration reaction kinetics using directly coupled HPLC-NMR: Application for the positional isomers of synthetic (2-fluorobenzoyl)-d-glucopyranuronic acid. Anal Chem 68:2564-2572.
23. Stopfer P, Kaiser R, Snelder N, Ploeger B, Staab A. (2006a). A population pharmacokinetic model for BIBF 1120, a triple angiokinase inhibitor, in cancer patients after single and multiple oral dosing. Presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Prague, Czech Republic, 7-10 November, Poster 96.
24. Stopfer P, Roth W, Mross K. (2006b). Pharmacokinetic characterization of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in advanced cancer patients. Presented at AACRNCI- EORTC International Conference on Molecular Targets and Cancer Therapeutics Prague, Czech Republic, Poster 73.